TABLE 1.
CSP (4–0.06 μg/mL) |
VCZ (4–0.06 μg/mL) |
ITZ (8–0.125 μg/mL) |
MFS (16–0.25 μg/mL) |
ML (16–0.25 μg/mL) |
TRB (4–0.06 μg/mL) |
AMB (8–0.125 μg/mL) |
|||
---|---|---|---|---|---|---|---|---|---|
Ss 4820 | Y | MIC | >4 | >4 | 0.25 | 2 | 2 | 1 | 2 |
MFC | >4 | >4 | 0.5 | 2 | 2 | 1 | 2 | ||
M | MIC | >4 | >4 | 2 | 2 | 2 | 1 | 2 | |
MFC | >4 | >4 | >8 | 2 | 2 | 1 | 2 | ||
Ss 4821 | Y | MIC | >4 | >4 | 0.5 | 2 | 2 | 1 | 2 |
MFC | >4 | >4 | 2 | 2 | 2 | 1 | 2 | ||
M | MIC | >4 | >4 | 1 | 2 | 2 | 1 | 2 | |
MFC | >4 | >4 | >8 | 2 | 2 | 1 | 2 | ||
Ss 4822 | Y | MIC | >4 | >4 | 0.125 | 2 | 2 | 0.5 | 2 |
MFC | >4 | >4 | 0.25 | 2 | 2 | 0.5 | 2 | ||
M | MIC | >4 | >4 | 2 | 2 | 2 | 1 | 2 | |
MFC | >4 | >4 | >8 | 2 | 2 | 1 | 2 | ||
Sb 4823 | Y | MIC | >4 | >4 | 2 | 2 | 2 | 0.5 | 2 |
MFC | >4 | >4 | >8 | 2 | 2 | 0.5 | 2 | ||
M | MIC | >4 | >4 | 1 | 2 | 2 | 1 | 2 | |
MFC | >4 | >4 | >8 | 2 | 2 | 1 | 2 | ||
Sb 4824 | Y | MIC | >4 | >4 | 0.5 | 2 | 2 | 0.5 | >8 |
MFC | >4 | >4 | 1 | 2 | 2 | 0.5 | >8 | ||
M | MIC | >4 | >4 | 2 | 2 | 2 | 1 | 2 | |
MFC | >4 | >4 | >8 | 2 | 2 | 1 | 2 | ||
Sb 4858 | Y | MIC | >4 | >4 | 0.125 | 2 | 2 | 0.125 | 2 |
MFC | >4 | >4 | 2 | 2 | 2 | 0.125 | 2 | ||
M | MIC | >4 | >4 | 1 | 2 | 2 | 1 | 2 | |
MFC | >4 | >4 | >8 | 2 | 2 | 1 | 2 |
Ss: S. schenckii, Sb: S. brasiliensis, Y: yeast phase, M: mycelial phase; CSP: caspofungin, VCZ: voriconazole, ITZ: itraconazole, MFS: miltefosine, ML: milteforan, TRB: terbinafine, AMB: amphotericin B.